Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Liabilities and Shareholders Equity: 2019-2025

Historic Liabilities and Shareholders Equity for Pharming Group N.V (PHAR) over the last 5 years, with Sep 2025 value amounting to $473.8 million.

  • Pharming Group N.V's Liabilities and Shareholders Equity rose 11.34% to $473.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year decrease of 1.30%. This contributed to the annual value of $400.0 million for FY2024, which is 13.58% down from last year.
  • Pharming Group N.V's Liabilities and Shareholders Equity amounted to $473.8 million in Q3 2025, which was up 6.17% from $446.3 million recorded in Q2 2025.
  • Pharming Group N.V's 5-year Liabilities and Shareholders Equity high stood at $473.8 million for Q3 2025, and its period low was $382,323 during Q3 2022.
  • Its 3-year average for Liabilities and Shareholders Equity is $432.6 million, with a median of $429.8 million in 2023.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first slumped by 99.90% in 2022, then soared by 114,061.85% in 2023.
  • Pharming Group N.V's Liabilities and Shareholders Equity (Quarterly) stood at $397.3 million in 2021, then climbed by 7.17% to $425.8 million in 2022, then climbed by 8.70% to $462.9 million in 2023, then fell by 13.58% to $400.0 million in 2024, then rose by 11.34% to $473.8 million in 2025.
  • Its Liabilities and Shareholders Equity was $473.8 million in Q3 2025, compared to $446.3 million in Q2 2025 and $403.2 million in Q1 2025.